About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Pharmaceutical Feature: Cdk5 inhibitors as novel candidate ...Hawkings, EF Medical, EiRx Therapeutics Ltd, Elan IT, Eli Lilly ... Cdk5 differs from other members of the Cdk family being modulated by its activator, p35. ...

http://www.google.co.uk/search?hl=en&ned=uk&ie=UTF-8&q=CDK2+eirx&sa=N&tab=nw

Serono Sa European pharma mergers set to continue - S&P
LONDON (AFX) - The recent wave of mergers among European pharmaceutical
companies is set to continue, Standard & Poor's believes, driven by strong
global sales growth and the race to develop top-selling "blockbuster" drugs.
The recent surge of activity started in July, when Germany's Bayer AG bought
domestic rival Schering AG in a deal worth nearly 16.9 bln eur.
Since then Merck KGaA, which lost out in the battle for Schering, has bought
the majority stake in Switzerland's Serono SA for 16.6 bln sfr, Nycomed acquired
the pharmaceutical arm of Altana AG for 4.5 bln eur and Belgium's UCB swooped on
Schwarz Pharma AG, paying 4.4 bln eur.
Standard & Poor's Olaf Toelke said those deals, among mid-sized companies,
mainly reflect concerns about critical size.
"All the transactions, including the Bayer-Schering link-up, have taken
place in a market dominated by the need to fund ever-increasing R&D budgets in
the race for the next blockbuster drug," the credit analyst wrote.
A key concern for pharma companies at the moment is the productivity of
their research and development efforts. The cost of developing a new drug has
risen in the last 10 years, as research techniques and compounds have become
more complicated, and regulatory requirements more onerous.
Taking into account all the products that never make it to the market, the
cost of developing every drug that does reach the shelves is estimated at more
than 1 bln usd.
Medium-sized drug makers such as Merck KGaA and Serono, which do not have
the huge cash flow of large pharma groups, have been merging so R&D budgets can
be increased.
Meanwhile, S&P said that the larger European pharmaceutical companies'
above-industry-average global sales growth and strong cash generation is
increasing their flexibility for M&A activities.
Companies including Switzerland's Roche Holding AG and Britain's
GlaxoSmithKline PLC reported sales growth of about 10 pct in the second quarter
of 2006, compared with an average assumed industry growth of about 6-7 pct, they
noted.
"The rated companies should therefore experience a further strengthening of
their credit quality on average, in the absence of larger acquisitions," Toelke
wrote.
amy.brown@afxnews.com
ab/lam

MGI phara results out wednesday news on milestone payment to ERX expected for its trial of ZYC300

MGI Pharma
----------
http://www.eirx.com/eirx_heading_images/Vaccine%20Antigens%20v2.0.pdf#search=%22mgi%20pharma%20zyc300%22

http://www.mgipharma.com/

last chance tomorrow... MGI announce on 18th

Hello pot head, some good trading to day!! might see 1p on some positive news :)

I think it will go higher than that mate.. colorectal cancer news will be huge, it will show just how undervalued this is

WELL you could jsut be right long term !! lets hope :)

smiler
Theres certainly more interest in ERX and news must come eventually so a steady rise or a surge is on the cards.

it will be a surge and it will be either tomorrow or wednesday, I do know ERX have been chaing MGI for there licence money.. that much I have been told

MGI announce there results on wednesday, no doubt we will get an update on ZYC300 as I see from three website it has now completed trials ii. and now about to start iii, and we were told on the next trial we would be receiving a milestone payment!!!!!... must be quite a whopper

Driver that would be good could top up on GTL Then its low at the moment !

also note our clinical trials with OSI are at a closing stage, we are currently doing a clinical trials iii.... all we need now is approval

smiler
Good point if you get your timing right we know GTL is at least a 4 bagger so a top up from ERX would be a good strategy but I bet neither of us do it though.

True Its timing, my AEN is a none starter and my OXS is the same, dont talk about FAO & BLR MY BGF is up a bit today so that leaves ERX TO TOP UP GTL

incase any of you have missed this... I dare say it relates to us

Harnessing Healthy Bacteria to Fight Cancer University Study
17th October 2006

--------------------------------------------------------------------------------

Email this Page |

Commonly available health products containing live bacteria and special sugars could help to combat certain types of cancer, according to UU scientist Professor Ian Rowland.

In a lecture to a conference on the health benefits of probiotics, Professor Rowland described a number of studies in human volunteers that indicated that certain bacteria in found in probiotic drinks and yoghurts and novel sugars called prebiotics, may have anti-cancer effects in the bowel.

In one study conducted in Japan, patients who had had surgery to remove colorectal cancers or intestinal polyps, which can become cancerous if left untreated, were given the probiotic Lactobacillus casei or a placebo and the reappearance of tumours was followed over the next four years. The probiotic appeared to suppress the development of new tumours in these high risk patients by up to 35%.

Professor Rowland also described the results of an EC-funded project called Synbiotics and Human Cancer, which was a collaboration between eight research centres throughout Europe including the University of Ulster.

The subjects in this study, which will be published in the American Journal of Clinical Nutrition, were similar to those in the Japanese study were recruited at the cancer centre associated with University College Cork.

The volunteers were given a placebo or a capsule containing a mixture of probiotic bacteria along with a sugar called inulin, which is derived from chicory. Inulin is a prebiotic, a substance which cannot be digested in the upper intestine but which acts as a source of energy for beneficial bacteria further down in the large intestine.

At the end of the 12 week intervention period those polyp patients on the pro- and prebiotics had less DNA damage and a lower rate of cell proliferation in biopsies taken from their colons. Additionally pro- and prebiotic feeding resulted in improvements in certain characteristics of stool samples that may be indicative of reduced cancer risk.

Professor Rowland said: Whilst this evidence is not definitive, these studies do suggest that the extensive data showing anti-cancer activity of probiotics and prebiotics from experiments in animals and isolated cells may be applicable to humans, and that more studies in human volunteers are warranted.

Among the theories of how the bacteria can help combat cancer are:

The microbes may stimulate the immune system to recognize and attack cancer cells.
The probiotics may inactivate cancer-causing chemicals in the intestine.
The bacteria cause the cancerous cells to destroy themselves, a natural process called apoptosis.

Notes to Editors

The other centres involved in the study included: University College Cork; the Karolinska Institute in Stockholm; the University of Jena in Germany; the University of Florence; the Federal Research Centre for Nutrition in Karlsruhe, Germany and Valio Ltd in Helsinki. The project was coordinated by the Orafti Group in Belgium.

http://news.ulster.ac.uk/releases/2006/2725.html

article released one hour ago

OH we are based in cork are we not ;-)

Express
SHARE WHISPER: EIRX THERAPEUTICS (talk of a cancer treatment deal with a US
company)

Looks promising smiler o

HI SWW, Could be good news, could see the BIG 1P soon !!

Eirx Therapeutics was 0.02 firmer at 0.26, amid talk of a cancer treatment deal with a US company that could provide a boost to revenues. Gossips talk of a potential sum of 18 mln usd (9.6 mln stg), well above Eirx's 7.0 mln stg market captalisation.

newsdesk@afxnews.com

fjb/vjt

ITS A BLUE DAY TO DAY : ) 50K MAX BUY !!!!!